Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Choy, Edwin ^a,c,f   Butrynski, James E ^b   Harmon, David C ^a,c   Morgan, Jeffrey A ^b   George, Suzanne ^b   Wagner, Andrew J ^b   D'Adamo, David ^b   Cote, Gregory M ^a,c   Flamand, Yael ^b   Benes, Cyril H ^c   Haber, Daniel A ^a,c   Baselga, Jose M ^a,c,e   Demetri, George D ^b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLAPARIB; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EWING SARCOMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; MALE; MUSCLE WEAKNESS; NAUSEA; NONCARDIAC CHEST PAIN; PHASE 2 CLINICAL TRIAL; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; ADOLESCENT; BONE NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETREATMENT; SARCOMA, EWING; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RETREATMENT; SARCOMA, EWING; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920855943     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-813     Document Type: Article

References (14)

1. Ross KA, Smyth NA, Murawski CD, Kennedy JG: The biology of ewing sarcoma. ISRN Oncol 2013, 2013:759725.
2. Bacci G, Ferrari S, Mercuri M, Longhi A, Giacomini S, Forni C, Bertoni F, Manfrini M, Barbieri E, Lari S, Donati D: Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. J Pediatr Hematol Oncol 2003, 25:118-124.
3. McTiernan AM, Cassoni AM, Driver D, Michelagnoli MP, Kilby AM, Whelan JS: Improving outcomes after relapse in Ewing's Sarcoma: analysis of 114 patients from a single institution. Sarcoma 2006, 2006:83548.
4. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, Pappo AS: Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002, 94:561-569.
5. Shankar AG, Ashley S, Craft AW, Pinkerton CR: Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003, 40:141-147.
6. Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A: Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 2007, 49:190-195.
7. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS: Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005, 23:4354-4362.
8. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F: Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006, 45:469-475.
9. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
10. Hutchinson L: Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2010, 7:549.
11. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR: A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011, 104:750-755.
12. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB: Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 2011, 17:783-791.
13. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM: PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012, 72:1608-1613.
14. Simon R:Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.